Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine Expanded Access for Treatment-Resistant Depression
NCT04476446Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events (AEs) up to 6 months. Started Sep 2020; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04476446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04476446.